United Nations International Narcotics Control Board. Annual Report 2006. United Nations, 2007.
Hall, AP, Henry, JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth
2006; 96: 678–85.
Zhou, FC, Tao-Cheng, JH, Segu, L, Patel, T, Wang, Y. Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res
1998; 805: 241–54.
Battaglia, G, Yeh, SY, O'Hearn, E, Molliver, ME, Kuhar, MJ, De Souza, EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther
1987; 242: 911–6.
Ricaurte, GA, Yuan, J, McCann, UD. (+/-)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology
2000; 42: 5–10.
Szabo, Z, McCann, UD, Wilson, AA, Scheffel, U, Owonikoko, T, Mathews, WB, et al. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med
2002; 43: 678–92.
Easton, N, Marsden, CA. Ecstasy: are animal data consistent between species and can they translate to humans?
2006; 20: 194–210.
Green, AR, Mechan, AO, Elliott, JM, O'Shea, E, Colado, MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev
2003; 55: 463–508.
Hatzidimitriou, G, McCann, UD, Ricaurte, GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci
1999; 19: 5096–107.
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM–IV Axis I Disorders – Clinician Version (SCID–CV). American Psychiatric Press, 1997.
Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry
1961; 4: 561–71.
Spielberger, CE, Garsuch, RL, Lushene, RE. Manual for the State–Trait Anxiety Inventory. Consulting Psychologists Press, 1970.
Eysenck, HJ, Eysenck, SBG. Manual of the Eysenck Personality Scales (EPS Adult). Hodder and Stoughton, 1991.
Baddeley, A, Emslie, H, Nimmo Smith, I. The Spot-the-Word Test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol
1993; 32: 55–65.
Wilson, AA, Ginovart, N, Schmidt, M, Meyer, JH, Threlkeld, PG, Houle, S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem
2000; 43: 3103–10.
Bhagwagar, Z, Murthy, N, Selvaraj, S, Hinz, R, Taylor, M, Fancy, S, et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry
2007; 164: 1858–65.
Hinz, R, Selvaraj, S, Murthy, NV, Bhagwagar, Z, Taylor, M, Cowen, PJ, et al. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls. J Cereb Blood Flow Metab
2008; 28: 1478–90.
McCann, UD, Szabo, Z, Seckin, E, Rosenblatt, P, Mathews, WB, Ravert, HT, et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology
2005; 30: 1741–50.
Hammers, A, Koepp, MJ, Free, SL, Brett, M, Richardson, MP, Labbé, C, et al. Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp
2002; 15: 165–74.
Kish, SJ, Furukawa, Y, Chang, LJ, Tong, J, Ginovart, N, Wilson, A, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?
Nucl Med Biol
2005; 32: 123–8.
Logan, J, Fowler, JS, Volkow, ND, Wolf, AP, Dewey, SL, Schlyer, DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab
1990; 10: 740–7.
Innis, RB, Cunningham, VJ, Delforge, J, Fujita, M, Gjedde, A, Gunn, RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab
2007; 27: 1533–9.
Cunningham, VJ, Jones, T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab
1993; 13: 15–23.
Reneman, L, de Win, MM, van den Brink, W, Booij, J, den Heeten, GJ. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol
2006; 20: 164–75.
Buchert, R, Thomasius, R, Wilke, F, Petersen, K, Nebeling, B, Obrocki, J, et al. A voxel-based PET investigation of the long-term effects of “Ecstasy” consumption on brain serotonin transporters. Am J Psychiatry
2004; 161: 1181–9.
Reneman, L, Lavalaye, J, Schmand, B, de Wolff, FA, van den Brink, W, den Heeten, GJ, et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”): preliminary findings. Arch Gen Psychiatry
2001; 58: 901–6.
Thomasius, R, Zapletalova, P, Petersen, K, Buchert, R, Andresen, B, Wartberg, L, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol
2006; 20: 211–25.
Thomasius, R, Petersen, K, Buchert, R, Andresen, B, Zapletalova, P, Wartberg, L, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl)
2003; 167: 85–96.
Fischer, C, Hatzidimitriou, G, Wlos, J, Katz, J, Ricaurte, G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). J Neurosci
1995; 15: 5476–85.
Fantegrossi, WE, Woolverton, WL, Kilbourn, M, Sherman, P, Yuan, J, Hatzidimitriou, G, et al. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology
2004; 29: 1270–81.
Verheyden, SL, Henry, JA, Curran, HV. Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. Hum Psychopharmacol
2003; 18: 507–17.
Reneman, L, Booij, J, de Bruin, K, Reitsma, JB, de Wolff, FA, Gunning, WB, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet
2001; 358: 1864–9.